S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:VTRS

Viatris (VTRS) Stock Price, News & Analysis

$13.53
+0.17 (+1.27%)
(As of 02/23/2024 ET)
Today's Range
$13.35
$13.62
50-Day Range
$10.10
$13.53
52-Week Range
$8.74
$13.62
Volume
13.34 million shs
Average Volume
8.46 million shs
Market Capitalization
$16.23 billion
P/E Ratio
8.96
Dividend Yield
3.55%
Price Target
$10.33

Viatris MarketRank™ Stock Analysis

Analyst Rating
Sell
1.33 Rating Score
Upside/​Downside
23.6% Downside
$10.33 Price Target
Short Interest
Healthy
2.86% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.08mentions of Viatris in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$331,960 Sold Last Quarter
Proj. Earnings Growth
-6.38%
From $2.98 to $2.79 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

Medical Sector

707th out of 943 stocks

Pharmaceutical Preparations Industry

326th out of 435 stocks


VTRS stock logo

About Viatris Stock (NASDAQ:VTRS)

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

VTRS Stock Price History

VTRS Stock News Headlines

Viatris Reduces Debt But Faces Growth Hurdles
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
SPY ETF Update, 2/20/2024
VTRS Jan 2025 15.000 call
VTRS Oct 2024 12.000 call
VTRS Jan 2026 15.000 put
VTRS Mar 2024 12.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Wall Street Breakfast: What Moved Markets
VTRS Mar 2024 10.000 call
SPY ETF Update, 2/16/2024
Viatris Inc.
5 Pharma Stocks to Watch With Bullish Momentum
SPY ETF Update, 2/8/2024
SPY ETF Update, 2/2/2024
3 Lucrative Pharma Stocks for Portfolio Success
SPY ETF Update, 1/29/2024
Viatris Inc. Common Stock (VTRS)
See More Headlines
Receive VTRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viatris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2023
Ex-Dividend for 12/15 Dividend
11/22/2023
Dividend Payable
12/15/2023
Today
2/24/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTRS
Employees
37,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.33
High Stock Price Target
$11.00
Low Stock Price Target
$9.00
Potential Upside/Downside
-23.6%
Consensus Rating
Sell
Rating Score (0-4)
1.33
Research Coverage
3 Analysts

Profitability

Net Income
$2.08 billion
Pretax Margin
16.34%

Debt

Sales & Book Value

Annual Sales
$15.47 billion
Cash Flow
$5.93 per share
Book Value
$17.38 per share

Miscellaneous

Outstanding Shares
1,199,671,000
Free Float
1,196,552,000
Market Cap
$16.23 billion
Optionable
Optionable
Beta
1.12
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Scott Andrew Smith (Age 62)
    CEO & Director
  • Mr. Rajiv Malik (Age 63)
    President & Executive Director
    Comp: $15.35M
  • Mr. Sanjeev Narula (Age 63)
    Chief Financial Officer
    Comp: $2.71M
  • Mr. Anthony Mauro (Age 51)
    President of Developed Markets
    Comp: $9.39M
  • Mr. Sanjeev Kumar Sethi (Age 57)
    Chief Operating Officer
  • Mr. Paul B. Campbell (Age 56)
    Chief Accounting Officer, Senior VP & Corporate Controller
  • Mr. Brian S. Roman (Age 54)
    Global General Counsel
  • Mr. David Bayles
    Chief Compliance Officer
  • Ms. Jennifer Mauer
    Head of Global Communications & Corporate Brand
  • Mr. Andrew Enrietti
    Chief Human Relations Officer














VTRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Viatris stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viatris in the last year. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" VTRS shares.
View VTRS analyst ratings
or view top-rated stocks.

What is Viatris' stock price target for 2024?

3 equities research analysts have issued 1-year price objectives for Viatris' stock. Their VTRS share price targets range from $9.00 to $11.00. On average, they predict the company's share price to reach $10.33 in the next twelve months. This suggests that the stock has a possible downside of 23.6%.
View analysts price targets for VTRS
or view top-rated stocks among Wall Street analysts.

How have VTRS shares performed in 2024?

Viatris' stock was trading at $10.83 on January 1st, 2024. Since then, VTRS shares have increased by 24.9% and is now trading at $13.53.
View the best growth stocks for 2024 here
.

Are investors shorting Viatris?

Viatris saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 33,720,000 shares, an increase of 9.2% from the January 15th total of 30,880,000 shares. Based on an average daily volume of 9,210,000 shares, the short-interest ratio is presently 3.7 days. Approximately 2.9% of the company's shares are sold short.
View Viatris' Short Interest
.

When is Viatris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our VTRS earnings forecast
.

How can I listen to Viatris' earnings call?

Viatris will be holding an earnings conference call on Wednesday, February 28th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Viatris' earnings last quarter?

Viatris Inc. (NASDAQ:VTRS) released its earnings results on Monday, August, 7th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.71 by $0.49. The firm earned $3.91 billion during the quarter, compared to the consensus estimate of $3.86 billion. Viatris had a net margin of 11.84% and a trailing twelve-month return on equity of 17.27%. The company's quarterly revenue was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.88 earnings per share.
Read the conference call transcript
.

How often does Viatris pay dividends? What is the dividend yield for Viatris?

Viatris announced a quarterly dividend on Monday, November 6th. Stockholders of record on Friday, November 24th will be given a dividend of $0.12 per share on Friday, December 15th. This represents a $0.48 annualized dividend and a dividend yield of 3.55%. The ex-dividend date is Wednesday, November 22nd.
Read our dividend analysis for VTRS
.

Is Viatris a good dividend stock?

Viatris (NASDAQ:VTRS) pays an annual dividend of $0.48 per share and currently has a dividend yield of 3.63%. The dividend payout ratio is 31.79%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, VTRS will have a dividend payout ratio of 17.20% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for VTRS.

How will Viatris' stock buyback program work?

Viatris declared that its board has approved a share buyback program on Monday, February 28th 2022, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 7.5% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's management believes its shares are undervalued.

What is Michael Goettler's approval rating as Viatris' CEO?

8 employees have rated Viatris Chief Executive Officer Michael Goettler on Glassdoor.com. Michael Goettler has an approval rating of 85% among the company's employees.

Who are Viatris' major shareholders?

Viatris' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.86%), Price T Rowe Associates Inc. MD (4.12%), Pacer Advisors Inc. (1.74%), Rubric Capital Management LP (1.46%), Dimensional Fund Advisors LP (1.02%) and Norges Bank (0.97%). Insiders that own company stock include Andrew Cuneo, Der Meer Mohr Pauline Van, Menassie Taddese, Michael Goettler, Robert J Coury, W Don Cornwell and Xiangyang (Sean) Ni.
View institutional ownership trends
.

How do I buy shares of Viatris?

Shares of VTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTRS) was last updated on 2/24/2024 by MarketBeat.com Staff